Thermo Fisher Scientific will acquire Life Technologies for approximately US$13.6 billion plus the assumption of net debt of $2.2 billion as of year end 2012.
The transaction will create a company focused on serving research, specialty diagnostics and applied markets. The combination builds on both companies’ technological strengths to accelerate results for life sciences customers working in proteomics, genomics and cell biology.
“We are extremely excited about this transaction because it creates the ultimate partner for our customers and significant value for our shareholders,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The acquisition of Life Technologies enhances all three elements of our growth strategy: technological innovation, a unique customer value proposition and expansion in emerging markets.
Life provides innovative products and services to customers conducting scientific research and genetic analysis, as well as those in applied markets, such as forensics and food safety testing.
With 2012 revenues of US$3.8 billion, its offering includes a range of reagents, consumables, instruments and systems. Life’s technologies are protected by approximately 5,000 patents and licenses.
In Australia, Life Technologies is based in Mulgrave, Victoria.